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Targeting the MAP Kinase pathway in Human Acute Myeloid 
Leukemia Cells using a recombinant Anthrax Lethal Toxin 
 
Elias Kassab 
 
Abstract 
In this study, we attempt to target the mitogen-activated protein kinase (MAPK) pathway 
in acute myeloid leukemia (AML) cells using a recombinant anthrax lethal toxin (LeTx). 
Around 15,000 new case of Acute Myeloid Leukemia are diagnosed each year with a 
fatality rate of 65%. The poor prognosis rate is due to the high proliferative and quick 
progressive characteristics of AML. However, most AML patients eventually relapse due 
to persistence of chemotherapy-resistant blasts in the bone marrow hence the need for 
alternative approaches employing novel, more selective mechanisms for targeting AML 
blasts. One such approach consists of targeting the mitogen-activated protein (MAP) 
kinase (MAPK) pathway in AML cells. LeTx consists of protective antigen (PrAg) and 
lethal factor (LF). PrAg binds cells, is cleaved by furin, oligomerizes, binds three to four 
molecules of LF, and undergoes endocytosis, releasing LF into the cytosol. LF cleaves 
MAPK kinases, inhibiting the MAPK pathway. The MAKP pathway is a conserved 
pathway between eukaryotes. Through a wide range of extracellular signals, the MAPK 
pathway regulates growth, proliferation, differentiation and death. Its constitutive 
activation, particularly the Ras/Raf/MEK1/2/ERK1/2 cascade promotes proliferation and 
survival of most human cancer cells.  
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We tested potency of LeTx on a panel of 11 human AML cell lines. Seven cell lines 
showed cytotoxic responses to LeTx. Cytotoxicity of LeTx was mimicked by the specific 
mitogen-activated protein/extracellular signal–regulated kinase kinase 1/2 (MEK1/2) 
inhibitor U0126, indicating that LeTx-induced cell death is mediated through the 
MEK1/2–extracellular signal–regulated kinase (ERK1/2) branch of the MAPK pathway. 
The four LeTx-resistant cell lines were sensitive to the phosphatidylinositol 3-kinase 
inhibitor LY294002. Flow cytometry analysis of MAPK pathway activation revealed 
presence of phospho-ERK1/2 only in LeTx-sensitive cells. In this study, we have shown 
that a majority of AML cell lines are sensitive to the LF-mediated inhibition of the 
MAPK pathway. Furthermore, we have demonstrated that LeTx-induced cytotoxicity in 
AML cells is non-apoptotic and dependent on phospho-ERK1/2 levels. 
 
Keywords: Mitogen-Activated Protein Kinase, Acute Myeloid Leukemia, Anthrax 
Lethal Toxin, ERK1/2, MEK1/2, Cytotoxicity, Flow Cytometry, Western Blot.  
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GLOSSARY 
AML         Acute myeloid leukemia 
LeTx         Anthrax lethal toxin 
PrAg         Protective antigen 
LF         Lethal Factor 
ANTXRs     Anthrax toxin receptors 
TEM-8         Tumor endothelium marker 8 
CMG-2         Capillary Morphogenesis Gene 2 
MAPK          Mitogen-activated protein kinase 
JNK          c-Jun NH2-terminal kinase 
Gab1          Grb2-associated binder 1 
PH         Plekstrin Homology 
TNF-α         Tumor necrosis factor- α 
MEK         Mitogen-activated protein kinase kinase 
ERK         Extracellular signal-regulated kinase 
SEK1         SAPK-stress-activated protein kinase-/c-Jun NH2-terminal kinase /Erk     
                    kinase 
MLK         Mixed-lineage kinase 
ASK1         Apoptosis signal-regulating kinase 1 
xv 
 
PAI-1        Plasminogen activator inhibitor- 1 
MMP        Metalloprotease 
FP59        Pseudomonas aeruginosa exotoxin A 
EF-2        Elongation factor 2 
Ras        Rat-adeno-sarcoma 
RTK        Receptor tyrosine kinase 
GRB2        Growth factor receptor-bound protein 2 
SOS        Son of Sevenless 
GEF        Guanine nucleotide exchange factor 
PI3K        Phosphatidylinositol 3-kinase 
PI(4,5)P2    Phosphatidylinositol 4,5-bisphosphate 
PDK1         3-phosphoinositide-dependent protein kinase-1 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Overview of Acute Myeloid Leukemia 
According to The American Cancer Society, the 2013 estimates for Leukemia of all kinds 
in the United States are approximately 48,610 newly diagnosed cases with approximately 
23,720 deaths. Acute Myeloid Leukemia (AML) is one of the most common leukemias in 
adults with an estimated 14,590 newly diagnosed cases in 2013, mainly in adults, and an 
estimated 10,370 deaths. AML is usually common in older individuals and rarely 
diagnosed in people below the age of 40, with the mean age of 67 for patients diagnosed 
with AML. The lifetime risk of acquiring AML in the average man is approximately 1 in 
232 while in the average woman is 1 in 278, hence making AML slightly more frequent 
in men than women (American Cancer Society, 2013). AML is highly proliferative and 
its quick progression with the lack of effective treatment has a very poor prognosis. 
According to the World Health Organization (WHO), AML is classified into four 
different subtypes according to clinical and genetic factors. On the other hand, the 
French-American-British (FAB) organization classifies AML into eight different 
subtypes, M0 to M7, depending on the cell type and degree of maturity. Over the past 
three decades, new therapeutic schemes have been developed that were successful in 
increasing complete remission in patients following combination induction and 
consolidation chemotherapy (American Cancer Society, 2013). The widely used 
chemotherapeutic agents are “Cytarabine”, “Doxorubicin” and “Mitoxantrone”. 
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Radiotherapy is an option for AML patients followed by bone marrow transplant from an 
appropriate donor. However, most patients eventually relapse due to persistence of 
chemotherapy-resistant blasts in the bone marrow (Bennett JM, 2002). Relapse rates 
differ depending on the patient and the AML subtype, the rates range from 33% to 78% 
with an average of 50%. Such patients with refractory and relapsed AML, unfortunately, 
have no effective therapeutic options, with the disease remaining incurable in most 
(Bennett JM, 2002). Hence, alternative approaches employing novel, more selective 
mechanisms for targeting AML blasts are being sought. One such approach consists of 
targeting the mitogen-activated protein (MAP) kinase (MAPK) pathway in AML cells 
using a recombinant anthrax lethal toxin (LeTx) (Davies SP, 1999) (Koo HM, 2002) 
(Abi-Habib RJ U. J., 2005). 
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1.2 Targeting the MAPK pathway 
The potential for targeting the MAPK pathway in AML has not been fully investigated 
yet. A number of studies have been carried out in the past years investigating the role 
played by the MAPK pathway in AML cell lines and in blasts from AML patient with 
very few studies attempting to target the MAPK pathway in AML. In one study, Non-
steroidal anti-inflammatory drugs (NSAIDs), were analyzed and proved to induce 
apoptosis in both AML cell lines and patient samples through the constitutive activation 
of c-Jun N-terminal kinases (JNKs), which are part of the MAPK family (Singh R, 2011). 
Another study conducted showed the important role of the MAPK pathway in blocking 
the oxidative stress induced senescence in AML (Xiao Y, 2012). Nargenicin, a polyketide 
antibiotic, was demonstrated as a possible treatment of neoplastic diseases, through its 
role in enhancing leukemia cell differentiation by targeting the 
PKCbeta1/MAPK pathways (Kim SH, 2009).        
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1.3 The MAPK pathway 
The MAPK pathway is a highly conserved signaling pathway among all eukaryotes; it 
plays a key role in the transduction of a wide range of extracellular signals. Such signals 
have a critical role in regulating growth, proliferation, differentiation and apoptosis in 
eukaryotic cells. Constitutive activation of the MAPK pathway leads to cell proliferation 
and survival in most human cancers (Abi-Habib RJ U. J., 2005) (Wellbrock C, 2004). 
 
Figure 1. Schematic overview of the Mitogen-Activated Protein Kinase Pathway (AS 
Dhillon, 2007).  
 
As depicted in figure 1, a three tier kinase module makes up the MAPK pathway where 
the phosphorylation of one (MAPKKK), is activated and in turn phosphorylates its 
downstream processor, therefore activating the pathway. Specific abnormalities and 
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deviations in the MAPK signaling pathway enhance the development and progression of 
cancer cells through the acquirement of capabilities such as: liberty of proliferation 
signals, apoptotic evasion, lack of sensitivity to anti-growth signals, infinite replication 
potential, angiogenis, invasion, metastasis, drug resistance and resistance to oncogene 
induced senescence.  As seen in figure 1, activated Raf will, through phosphorylation, 
activate MEK1 and MEK2. There exists three different isoforrms that differ in their 
abilities to activate both MEK1/2. Raf-1 is one of the Raf isoforms that efficiently 
activates both MEK1/2 equally. Once ERK1/2 is activated by MEK, it phosphorylates 
several cytoplasmic and nuclear targets such as kinases, phosphatases, cytoskeletal 
proteins and transcription factors. These ERK signals will in-turn regulate the processes 
related to cell development and progression discussed earlier. Mutations leading to the 
constitutive activation of the Ras-Raf-MEK1/2-ERK1/2 pathway are a hallmark of 
several tumors such as melanoma and are found in a variety of cancers, including AML, 
thus constituting an attractive target for novel AML therapies (Lee JT Jr, 2002) (Hilger 
RA, 2002) (Wu, 2004) (Milella M K. S., 2001) (AS Dhillon, 2007). 
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1.4 Anthrax Lethal Toxin 
LeTx is a binary toxin produced by the gram positive bacterium Bacillus anthracis and 
consisting of two separate proteins: the cell binding and internalization moiety protective 
antigen (PrAg) and the catalytic moiety lethal factor (LF) (Bradley KA M. J., 2001) 
(Scobie HM, 2003). PrAg binds to cells through its ubiquitously expressed cell surface 
receptors tumor endothelial marker-8 (TEM-8) and capillary morphogenesis gene-2 
(CMG-2), collectively referred to as anthrax toxin receptors (ANTXRs). Both TEM-8 
and CMG-2 show a high degree of similarity; they are ubiquitously expressed type-1 
transmembrane proteins, with each having an ectodomain (extracellular domain), a 
single-pass transmembrane domain and a cytoplasmic domain. The gene Cmg2 is 
expressed all over the human body with the exception of the human brain, however the 
exact role Cmg2 is still largely unknown. TEM-8, being a tumor marker on one hand, 
might also play a role in angiogenesis since both Tem8 and Cmg2 genes have been found 
to be upregulated during angiogenesis (Deuquet J, 2012).  
 Following binding to its receptors, PrAg is cleaved at the sequence, 164RKKR167, by 
cell surface furin-like proteases leading to the release of a 20-kDa fragment and the 
generation of an active 63-kDa fragment (PrAg63) (Abi-Habib RJ U. J., 2005) (Abrami L 
L. S., 2003). The latter then forms oligomers, bind 3-4 molecules of LF and undergo 
receptor-mediated endocytosis (Abrami L L. S., 2006).Upon acidification of the 
endosome, PrAg63 oligomers undergo a conformational change leading to a cation-
dependent pore formation and allowing LF to translocate into the cytosol (Melnyk PA, 
2006) . LF is a zinc metalloprotease that cleaves and inactivates all mitogen-activated 
protein/extracellular regulated kinase kinases (MEKs), leading to the inhibition of the 
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MAPK pathway and subsequent growth inhibition and cell death. (Duesbery NS, 1998) 
(Chopra AP, 2003) (Abi-Habib RJ S. R., 2006) 
 
Figure 2. Mechanism of action of Anthrax Toxin (Moayeri, 2004) 
We have previously shown that cytotoxicity of LeTx to human melanoma cell lines 
carrying the V600E BRAF mutation is dependent on the activation status of the MAPK 
pathway, particularly MEK1/2, allowing the use of this toxin for the selective targeting of 
tumors with constitutive MAPK activation (Koo HM, 2002) (Abi-Habib RJ U. J., 2005) 
(Wu, 2004) (Milella M K. S., 2001) (Abi-Habib RJ S. R., 2006) 
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1.5 Previous work 
We and others have previously demonstrated the potency and selectivity of LeTx to 
melanoma cell lines in vitro and in an in vivo melanoma model (Abi-Habib RJ U. J., 
2005) (Koo HM, 2002). However, unlike melanoma, in which the importance of N-Ras 
and BRAF mutations (found in up to 95% of cases) is well established, the importance of 
MAPK pathway mutations in AML has been poorly investigated (Zaidi SK, 2009). 
Moreover, very few attempts have been made to target the MAPK pathway in AML, with 
the exception of targeting the receptor tyrosine kinase FLT3 (fms-like tyrosine kinase) in 
AML cells carrying FLT3 mutations (Ricciardi M, 2012) (Konopleva M, 2005). Hence, a 
deeper investigation of the role played by the MAPK pathway in human AML cell lines 
along with the possibility of selectively targeting AML through the inhibition of the 
MAPK pathway are warranted. 
In this study, we attempt to target the MAPK pathway in AML cell lines using a 
recombinant anthrax lethal toxin and to characterize the response of AML cells to the 
LeTx-mediated inhibition of the MAPK pathway. 
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CHAPTER TWO 
MATERIALS AND METHODS 
Expression and purification of PrAg, LF and FP59: 
Recombinant anthrax lethal toxin (LeTx) proteins PrAg and LF, as well as FP59 (fusion 
of the PrAg binding domain of LF and the catalytic domain of Pseudomonas aeruginosa 
exotoxin A) were expressed and purified in the laboratory of Stephen H. Leppla at the 
National Institute of Allergies and Infectious Diseases (NIAID) of the National Institutes 
of Health (NIH) in Bethesda, MD, as described previously (Ramirez DM, 2002) (Liu S, 
2001). Briefly, fermentation was carried out by inoculating a 12 to 14 h old starter culture 
grown from a frozen stock. Three to ten liter fermentations were carried out controlling 
dissolved oxygen (DO) at 30% saturation, temperature at 37
o
C, and pH at 7.5. At harvest 
time, 5 mM EDTA and 10 ug/ml PMSF (phenylmethyl sulfonyl fluoride) were added to 
the culture. Purification was then carried out as follows: 1. Packed-bed hydrophobic 
interaction chromatography during which the cell suspension was centrifuged and the 
supernatant was passed through a 0.2 -µm hollow fiber filter (AGT, Needham, MA). The 
filtered broth was then concentrated 20 fold using a 10K membrane. After sample 
loading, the column was washed with 10 column volumes (CV) of equilibration buffer 
and rPA was eluted with a 30 CV linear gradient of (NH4)2SO4 in 10 mM HEPES, 5 
mM EDTA. The rPA-containing fractions were pooled for further purification. 2-
Expanded-bed hydrophobic interaction chromatography in which the cell suspension was 
diluted 1:1 with buffer and the diluted cell suspension was loaded upward at 300 cm/ h. 
The column was washed in expanded mode with 10 CV of equilibration buffer. Elution 
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was performed in packed-bed mode with 8 CV of elution buffer at 100 cm/ h. 3- Anion 
exchange chromatography in which fractions from HIC were dialyzed against 20 mM 
Tris pH= 8.9/ 5 mM EDTA and loaded on a Q Sepharose Fast Flow (Amersham 
Pharmacia Biotech) column. The protein was eluted using a 20 CV linear gradient of 
NaCl in the same buffer. rPA-containing fractions were concentrated and dialyzed against 
PBS. (Ramirez DM, 2002) (Liu S, 2001)  
LY294002 was purchased from Cell signaling Technology (Danvers, MA).  
 
Cells and cell lines: 
Human AML cell lines HL60, U937, ML2, Mono-Mac-1, Mono-Mac-6, KG-1, SigM5, 
TF1-vRaf, TF1-vSrc and TF1-HaRas were grown in RPMI 1640 medium with 10% heat-
inactivated fetal bovine serum supplemented with penicillin/streptomycin and l-
glutamine. ML1 was grown in Iscove’s modified Dulbecco’s medium with 10% heat-
inactivated fetal bovine serum (FBS) supplemented with penicillin/streptomycin and l-
glutamine (Ramage J, 2003).
24
 Cells were maintained in a water-jacketed CO2 incubator 
at 37
o
C/5%CO2 and passaged every 2 to 3 days into new flasks containing fresh media. 
Human CD34
+
 progenitor bone marrow blasts (PBMBs) were purchased from (Lonza, 
Basel, Switzerland) and grown in StemlineII
TM
 hematopoietic stem cell expansion 
medium (Sigma-Aldrich) supplemented with 10 ng/ml IL-3, 5 ng/ml granulocyte colony 
stimulating factor (G-CSF), 5 ng/ml granulocyte macrophage colony stimulating factor 
(GMCSF), 10 ng/ml stem cell factor (SCF), 10 µg/ml insulin and 100 µg/ml transferrin 
(Sigma-Aldrich), as described previously (Blair A, 1998). 
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Proliferation inhibition assay (cytotoxicity): 
Sensitivity of AML cell lines and CD34
+ 
Progenitor Bone Marrow Blasts (PBMBs) to 
LeTx was determined using a proliferation inhibition assay as described previously (Abi-
Habib RJ U. J., 2005) We have also used a recombinant protein, termed FP59, consisting 
of the PrAg binding domain of LF fused to the catalytic domain of Pseudomonas 
aeruginosa exotoxin A. Binding of FP59 to PrAg and its translocation into the cytosol are 
identical to those of LF, however, it does not target the MAPK pathway but rather ADP-
ribosylates elongation factor 2 (EF-2) leading to inhibition of protein synthesis and cell 
death. PrAg/FP59 was used as a control for catalytic domain entry into the cytosol of 
AML cells. Briefly, aliquots of 10
4
 cells/well, in 100 l cell culture medium, containing a 
fixed concentration of 10
-9
 M LF or FP59, were plated in a flat-bottom 96-well plate 
(Corning Inc. Corning, NY). Then, 50 l PrAg in media were added to each well to yield 
concentrations ranging from 10
-8
 to 10
-13
 M. When LY294002 or U0126 were used, they 
were added as described above for PrAg but in concentrations ranging from 10
-4
 to 10
-9
 
M. Following a 48 h incubation at 37
o
C/5% CO2, 50 l of XTT cell proliferation reagent 
(Roche, Basel, Switzerland) were added to each well and the plates incubated for another 
4 h. Absorbance was then read at 450 nm using a microplate reader (Thermo Fisher 
Scientific, Waltham, MA). Nominal absorbance and percent maximal absorbance were 
plotted against the log of concentration and a non-linear regression with a variable slope 
sigmoidal dose-response curve was generated along with IC50 using GraphPad Prism 5 
software (GraphPad Software, San Diego, CA). All assays were performed at least twice 
with an inter-assay range of 30% or less for IC50.  
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Cell cycle analysis: 
The impact of LeTx treatment on the cell cycle of AML cells was determined using 
Propidium Iodide (PI)-staining on flow cytometry. Briefly, cells incubated with 3 
different concentrations of LeTx (10,000, 300 and 4.5 pM) or media alone in flat-bottom 
96-well plates (Corning Inc. Corning, NY) for 24 and 48 h at 37
o
C/5% CO2, were 
harvested and fixed in 70% ethanol for a minimum of 24 h, at -20
o
C. Cells were then 
incubated in 500 l PI staining solution (50 µg/ml) for 40 min at 37oC. Samples were 
then read on a C6 flow cytometer (BD Accuri, Ann Arbor, MI) and total cell DNA 
content was measured on FL2-A. Percent of cells in G0/G1, S and G2/M phase was 
determined in control cells and in cells treated with the 3 different concentrations of LeTx 
(10,000, 300 and 4.5 pM) following gating for the cell population on width versus 
forward scatter. 
Inhibition Assays 
AML cells were incubated with either the small molecular weight PI3 kinase (PI3K) 
inhibitor LY294002 (Cell Signaling Technology, Danvers, MA) alone and in 
combination with LeTx or with the small molecular weight MEK1/2 inhibitor U0126 
(Cell Signaling Technology, Danvers, MA). Briefly, 10
4
 cells/well were plated in 100 l 
of medium in a flat-bottom, 96-well plate. Then 100 l of either medium (control cells) 
or medium containing LeTx (10
-8
M PrAg/10
-9
M LF), LY294002 (20 and 50 µM), U0126 
(20 and 50 µM) or a combination of the above were added. Cells were then incubated for 
48 h at 37
o
C/5% CO2 followed by the addition of 50 l of XTT cell proliferation reagent 
(Roche, Basel, Switzerland). Cells were incubated for another 4 h and absorbance was 
read at 450 nm using a 96-well plate reader (Thermo Fisher Scientific, Waltham, MA). 
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Data was analyzed using GraphPad Prism V software (GraphPad Software, San Diego, 
CA). The absorbance and the percent absorbance of controls were compared between the 
different treatment groups.  
Protein Extraction and Western Blotting 
10 x 10
6 
cells of each of the 11 cell lines were isolated, centrifuged at 1500 rpm for 5 
min. Cells were then re-suspended in Cell Lytic™ Mamalian Cell Lysis Reagent (Sigma-
Aldrich) with 1% protease inhibitor (M221, Protease Inhibitor Cocktails, Amresco, USA) 
then centrifuged at 1500 rpm for 5 min. The supernatant was collected and stored at -80 
o
C. All protein samples used for western blotting were prepared in the same way; 8 l of 
each sample were added to 10 l of Protein Loading buffer (ProSieve®ProTrack™ Dual 
Color, Lonza, Rockland USA) and 2 l DTT, for a total of 20 l. 10% polyacrylamide 
precast 10-well gels (Bio-Rad) were used. 10 l of a Biotinylated protein ladder (Cell 
Signaling Technology, Danvers, MA) was loaded in the first well. Bio-Rad Mini-
PROTEAN® Tetra System Electrophoresis apparatus was used for running at 120 Volts 
and transfer at 0.25 mA on nitro-cellulose membrane. Running buffer used consisted of 
60% glycine, 30% Tris-base and 10 % SDS at a pH of 8.4. The transfer buffer used was 
prepared using 20% running buffer with 20% methanol and 60% distilled water. The 
membranes were blocked overnight using 5% BSA and 0.1% Tween 20. The membranes 
were then incubated for 1 hour with the primary anti-phospho-ERK1/2 (Ser217/221) or 
anti-ERK1/2 (Thr202/Tyr204) rabbit monoclonal antibodies (Cell Signaling Technology, 
Danvers, MA) in antibody binding buffer, and then washed using a washing buffer (TBS 
+ 0.5% Tween 20) three times each for 15 min. After washing, the membranes were 
incubated with the secondary FITC-conjugated mouse anti-rabbit polyclonal antibody 
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(Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hr and then washed three times for 15 
min as described before. Development was done using Bio-Rad Molecular Imager® 
(ChemiDoc™XRS+, bio-Rad USA) Imaging System. Band intensity was analyzed using 
Quantity One® Software (Bio-Rad Laboratories, Inc., ©1998, version 4.6.9.30) and the 
ratio of Phospho ERK to ERK was determined.                 
Intracellular Staining and Flow Cytometry Analysis 
Activation of the MEK1/2-ERK1/2 pathway in AML cell lines [untreated and following a 
10-hour incubation with LeTx (10-8M PrAg/10-9M LF)] was assessed by determining 
the presence or absence of phospho-ERK1/2 using flow cytometry as described 
previously.
25
 Approximately 3x10
6
 cells were fixed in 70% ethanol for 15 min. Cells 
were then incubated with a 1/100 dilution of anti-phospho-ERK1/2 (Ser 217/221) rabbit 
monoclonal antibodies (Cell Signaling Technology, Danvers, MA) in antibody binding 
buffer containing 0.05% Triton-X 100, for 1 h at 37
o
C, followed by a 30-minute 
incubation with a 1/100 dilution of a FITC-conjugated mouse anti-rabbit polyclonal 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Fixed cells stained only with 
FITC-conjugated mouse anti-rabbit polyclonal antibody were used as isotypic control. 
Samples were then analyzed using a C6 flow cytometer (BD Accuri, Ann Arbor, MI). 
The presence of Phospho-ERK1/2 was analyzed and compared with that of the isotopic 
control. Positivity for the presence of phospho-ERK1/2 was determined using the ratio of 
fluorescence intensity (RFI) between the mean fluorescence intensity (MFI) of the 
stained cells and the MFI of the isotypic control. RFI  2 was considered positive. 
 
 
15 
 
Analysis of Cell Cytotoxicity: 
Determination of apoptotic versus non-apoptotic cell death was carried out using an 
Annexin V-fluorescin Isothiocyanate (Annexin V-FITC) and Propidium Iodide (PI) 
labeled apoptosis/necrosis detection kit (Abcam, Cambridge, MA) and a FITC-
conjugated active caspase inhibitor (ApoStat Apoptosis Detection Kit, R&D Systems, 
Abingdon, England) on flow cytometry. Briefly, 10
4
 cells/well were plated in 100 l 
media in a flat-bottom, 96-well plate and were incubated with either 100 l of medium 
alone (control cells) or medium containing three different concentrations of LeTx (as 
described above under cell cycle analysis) for 24 and 48 h at 37
o
C/5% CO2. Cells were 
then harvested and incubated with a FITC-conjugated annexin V antibody (2.5 mg/ml 
and PI (5 mg/ml) in antibody binding buffer for 45 min at 37
o
C or incubated with 0.5 
µg/ml of apostat for 30 min then harvested. Cells were then read using a C6 flow 
cytometer. Annexin V/PI data was analyzed on FL1-H versus FL2-H scatter plot and 
active caspases were detected on FL1-H. Unstained cells were used as negative control. 
Cells had to show positive annexin V staining, negative PI staining and positive active 
caspase staining to be considered apoptotic, while cells positive for both annexin V and 
PI staining and negative for active caspase staining were considered non-apoptotic. 
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CHAPTER THREE 
RESULTS 
Cytotoxicity of Anthrax Lethal Toxin: 
We tested the cytotoxicity of anthrax lethal toxin (LeTx) on a panel of 11 human acute 
myeloid leukemia (AML) cell lines using an XTT proliferation inhibition assay. Seven 
out of eleven AML cell lines (64%) were sensitive to the LF-mediated inhibition of the 
MAPK pathway with IC50 values ranging from 13 to94 pM and percent cell kill at highest 
concentration > 75%. The remaining 4 cell lines were not sensitive to the LF-mediated 
inhibition of the MAPK pathway with IC50 > 10,000 pM and percent cell kill at highest 
concentration ≤ 40% (Table 1, Fig. 3F). Human CD34
+
 Progenitor Bone Marrow Blasts 
(PBMBs), on the other hand, were not sensitive to the LeTx-mediated inhibition of the 
MAPK pathways indicating that LeTx selectively targets AML cells while sparing 
normal progenitor blasts. To demonstrate that resistance to LeTx was due to resistance to 
the LF-mediated inhibition of the MAPK pathway and not to the inability of LF to 
translocate into the cytosol of targeted cells, we tested the cytotoxicity of a combination 
of PrAg and FP59 to AML cell lines. FP59 is a fusion of the PrAg binding domain of LF 
and the catalytic domain of Pseudomonas aeruginosa exotoxin A. Binding to PrAg and 
translocation of FP59 into the cytosol are identical to those of LF, however, FP59 does 
not target the MAPK pathway but rather ADP-ribosylates elongation factor 2 (EF-2) 
leading to the inhibition of protein synthesis and subsequent cell death. The combination 
of PrAg and FP59, therefore, induces MAPK-independent cytotoxicity to all cells that 
express the anthrax toxin receptors. PrAg/FP59 was cytotoxic to all the AML cell lines 
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tested with IC50 = 0.7-18 pM and percent cell death > 90% indicating that differential 
sensitivity of AML cells to LeTx is independent of the ability of LF to translocate into the 
cytosol (Table 1, Figure 3A-D) and dependent on the addiction of cells to the MAPK 
pathway.  
 
Table 1. Sensitivity of human AML cell lines to LeTx (PrAg/LF), U0126 and the protein 
synthesis inhibitor PrAg/FP59. 
Cells and Cell 
lines 
LeTx (PrAg/LF) 
(IC50;pmol/L) 
PrAg/FP59 
(IC50;pmol/L) 
U0126   
(IC50;µmol/L) 
AML Cell lines    
HL60 13.0 0.7 2.6 
TF1-VSrc 15.0 3.0 2.0 
TF1-VRaf 16.0 4.0 1.3 
Mono-Mac-6 39.0 13.0 2.1 
SigM5 40.0 17.0 1.9 
ML-2 81.0 7.0 1.5 
TF1-HaRas 94.0 0.4 2.7 
ML-1 > 10000 6.0 > 1000 
U937 > 10000 1.0 > 1000 
KG-1 > 10000 1.0 > 1000 
Mono-Mac-1 > 10000 2.0 > 1000 
Normal Cells    
CD34
+
 BMPBs >  10000 10.0 N/A 
N/A: Not available 
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In addition, intracellular staining and flow cytometry analysis of phospho-ERK1/2 in 
sensitive cell lines before and after a10h incubation with LeTx revealed the absence of 
phospho-ERK1/2 in cells treated with LeTx, compared to non-treated cells, thus 
indicating that cytotoxicity of LeTx to AML cells is mediated through the proteolytic 
cleavage of MEKs by LF and subsequent inhibition of the MAPK pathway as evidenced 
by the absence on phospho-ERK1/2 in LeTx-treated cells (Data not shown). Moreover, 
since anthrax lethal toxin inhibits all branches of the MAPK pathway, it is possible that 
cytotoxicity of LeTx to AML cell lines is due to the simultaneous inhibition of all three 
branches of the MAPK pathway and not only the MEK1/2-ERK1/2 branch. Therefore, in 
order to determine the contribution of the MEK1/2-ERK1/2 branch to the cytotoxicity of 
LeTx, we tested the sensitivity of our panel of AML cell lines to U0126, the specific 
MEK1/2 inhibitor. Cytotoxicity of U0126 mimicked that of LeTx with the same pattern 
seen with both LeTx and U0126 across the panel of AML cell lines (Table 1, Figure 3G). 
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Figure 3. Non-Linear regression curves of LeTx (PrAg/LF) (square) and PrAg/FP59 
(triangle) on human AML cell lines and normal CD34
+
 BMPBs. HL60 (A) and TF1-vRaf 
(B) cell lines are sensitive to both LeTx and PrAg/FP59. Mono-Mac-1 (C), U937 (D) and 
CD34
+
 BMPBs (E) are only sensitive to PrAg/FP59 but not to PrAg/LF indicating 
resistance to the LF-mediated inhibition of the MAPK pathway. F) Compilation of LeTx 
non-linear regression curves on all AML cell lines tested. G) Non-linear regression 
curves of the specific MEK1/2 inhibitor U0126 on TF1-vRaf (square), HL60 (triangle), 
Mono-Mac-1 (inverted triangle) and U937 (diamond) cell lines. The LeTx-sensitive cell 
lines TF1-vRaf and HL60 are sensitive to U0126 while the LeTx-resistant cell lines 
Mono-Mac-1 and U937 are resistant to U0126.  
 
The four cell lines that were resistant to LeTx-induced cytotoxicity were also resistant to 
U0126 (IC50 > 1000 µM and percent cell kill at the highest concentration ≤ 35%), thus 
confirming that these cell lines do not rely on the MAPK pathway for survival and are 
resistant to both the specific inhibition of MEK1/2 and the inhibition of the entire MAPK 
pathway. The seven AML cell lines that were sensitive to LeTx-induced cytotoxicity 
were also sensitive to the specific MEK1/2 inhibitor U0126 (IC50 = 1.3-2.7 µM, percent 
cell kill at the highest concentration > 60%), thus indicating that cytotoxicity of LeTx is 
mediated through the inhibition of the MEK1/2-ERK1/2 branch of the MAPK pathway. 
 
Cell cycle effect of Anthrax Lethal Toxin: 
In order to determine whether, in addition to its cytotoxicity, LeTx induces cell cycle 
arrest in AML cells, we determined the cell cycle status of our panel of AML cell lines 
following 24 and 48 h incubation with three different concentrations of the LeTx. One of 
the four AML cell lines that were not sensitive to the cytotoxicity of LeTx (ML1) showed 
dose-dependent cell cycle arrest at 24 h (data not shown) and 48 h following treatment 
with LeTx, while the other three (U937, Mono-Mac-1 and KG-1) did not show any effect 
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of LeTx treatment on cell cycle (Fig. 4A and B). The fraction of cells in the G0/G1 phase 
of ML1 increased from approximately 39% and 34% of the total cell population in 
control cells to approximately 74% and 60% of the total cell population following 
incubation with 10,000 pM of LeTx for 24 and 48 h, respectively. This was associated 
with a corresponding decrease in the percentage of cells in the G2/M phase from 
approximately 10% and 19% of the cell population in control cells to approximately 7% 
and 8% of the cell population in treated cells at 24 and 48 h, respectively (Fig. 4A).  
 
A) 
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F) 
 
Figure 4. Cell cycle analysis of AML cell lines following treatment with LeTx. Control 
cells are represented in the left panels and cells treated with 10 nM LeTx for 48 h in the 
right panels. Cells are gated on width versus forward scatter (R1/R2). Cells in G0/G1 are 
gated M2, G2/M are gated M3 and pre-G0/G1 (dead) are gated M4 or M5. One of the cell 
lines that did not show a cytotoxic response to LeTx, ML1 (A), did show cell cycle arrest 
while the other, U937 (B), did not. Similarly, three of the LeTx-sensitive cell lines ML2 
(C), HL60 (D) and TF1-HaRas (E) showed cell cycle arrest in addition to cell death while 
another, TF1-vRaf (F), showed complete cell death following treatment. 
 
Furthermore, cell cycle arrest was observed in four out of the seven cell lines that showed 
a cytotoxic response to the LF-mediated inhibition of the MAPK pathway (ML2, HL60, 
TF1-HaRas and TF1-vSrc) at 24 h (data not shown) and 48 h following treatment with 
LeTx. A dose-dependent increase in the percentage of surviving cells in the G0/G1 phase 
was observed (42%, 58%, 41% and 40% in control cells versus 54%, 70%, 67% and 54% 
in treated cells) at 48 h, in ML2, HL60, TF1-HaRas and TF1-vSrc cells, respectively 
(Fig. 4C, D and ). This was associated with a corresponding decrease in the percentage of 
cells in the G2/M phase, by approximately 10%, in treated versus control cells in all four 
cell lines. The remaining three LeTx-sensitive cell lines [TF1-vRaf (Fig. 4D), SigM5 and 
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Mono-Mac-6], showed complete cell death with more than 90% of cells in the pre-G0/G1 
peak and no difference in the percentage of cells in the G0/G1 phase between control 
cells and surviving cells at the highest concentration of LeTx at both 24 h (data not 
shown) and 48-h incubation. This indicates that, in addition to significant cytotoxicity to 
the majority of AML cell lines, LeTx induces cell cycle arrest in a subset of AML cells 
(approximately 45%) irrespective of their cytotoxic response to the LF-mediated 
inhibition of the MAPK pathway. 
 
Inhibition of PI3 Kinase: 
In order to determine whether AML cell lines that are resistant to the LF-mediated 
inhibition of the MAPK pathway are susceptible to the inhibition of the PI3K/Akt 
pathway, we tested the sensitivity of the LeTx-resistant cell lines (ML1, Mono-Mac-1, 
U937 and KG-1) to the small molecular weight PI3K inhibitor LY294002. Incubation 
with LY294002 at 20 and 50 µM for 48 h induced significant cytotoxicity in all four cell 
lines with cell viability decreasing by approximately 40 to 50% at the 20 M 
concentration and 60 to 80% at the 50 M concentration compared to untreated cells (p < 
0.05) (Fig. 5A). Co-incubation of these cells with both LeTx (10 nM) and LY294002 (20 
and 50 M) led to only a slight decrease in cell viability, approximately 10%, compared 
to LY294002 alone. Although the decreases in cell viability observed following co-
incubation with both LeTx and LY294002 were statistically significant for the U937 cell 
line at the 20 M concentration, the ML1 cell line at the 50 M concentration and the 
Mono-Mac-1 and KG-1 cell lines at both the 20 and 50 M concentrations (P < 0.05), 
compared to LY294002 alone, they were not considered functionally significant since co-
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incubation only accounted for an additional decrease in cell viability of no more than 
10% compared to LY294002 alone (Fig. 5A). Moreover, cytotoxicity of the combination 
of LY294002 and LeTx was similar to the cytotoxicity of either LeTx alone or LY294002 
alone as evidenced by similar non-linear regression curves and similar IC50 values, at 48 
h, in a proliferation inhibition assay (Fig. 5 B, C and D).  
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Figure 5.  Sensitivity of LeTx-resistant AML cell lines to LY294002 alone and in 
combination with LeTx. A) LeTx resistant cell lines incubated with LY294002 at 20 and 
50 µM, for 48 h were sensitive to both concentrations of LY294002 while co-incubation 
with LeTx (10 nM) did not lead to any significant increase in sensitivity cell sensitivity. 
Non-linear regression curves of U937 (B), Mono-Mac-1 (C) and TF1-vSrc (D) cells 
incubated with LeTx (square), LY294002 (triangle) or a combination of both (inverted 
triangle). The combination of LeTx and LY294002 did not lead to increased cytotoxicity 
compared to either LeTx or LY294002 alone. 
 
Hence, cell lines that are not sensitive to LeTx are sensitive to the inhibition of the 
PI3K/Akt pathway with the simultaneous inhibition of both pathways not resulting in 
increased cell cytotoxicity. This shows the existence of two distinct populations of AML 
cell lines sensitive to the inhibition of either the MAPK pathway or the PI3K/Akt 
pathway with no additive or synergistic effect observed when both pathways are inhibited 
simultaneously. 
 
Analysis of MAPK Activation: 
We examined the activation level of the MAPK pathway in AML cell lines by 
determining the phosphorylation status of phospho-ERK1/2, using both single-cell 
intracellular staining on flow cytometry and western blotting. A representative sample of 
four AML cell lines was tested using single-cell intracellular staining, while lysates of the 
entire panel of AML cell lines were tested by western blot to determine the ratio of 
phosphor/total ERK1/2 levels.The presence or absence of phospho-ERK1/2 was linked to 
the cells response to the LF-mediated inhibition of the MAPK pathway.  
Both of the cell lines that showed a cytotoxic response to the LF-mediated inhibition of 
the MAPK pathway (ML-2 and TF1-vRaf) had an active MEK1/2-ERK1/2 pathway as 
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evidenced by the presence of phospho-ERK1/2 using single-cell intracellular staining 
(RFI = 2.14 and 2.32 for ML-2 and TF1-vRaf, respectively, compared to isotype control) 
(Fig. 6 A and B).  
A)                                                             B) 
 
C)                                                                  D) 
 
Figure 6. Single-cell, intracellular staining of Phospho-ERK1/2 in 4 AML cell lines 
using flow cytometry. TF1-vRaf (A) and ML-2 (B) cells, which showed a cytotoxic 
response to the LF-mediated inhibition of the MAPK pathway, were positive for the 
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presence of phospho-ERK1/2 as evidenced by a ratio of fluorescence intensity (RFI) > 2 
between cells stained for phospho-ERK1/2 (grey) and cells incubated with an isotype 
control (black). Cells are gated on width versus forward scatter (R2 and R3). ML-1 (C) 
and U937 (D) cells, which were resistant to the cytotoxicity of LeTx, were negative for 
phospho-ERK1/2 with RFI < 1.5. 
 
On the other hand, the two cell lines that did not show a cytotoxic response to the LF-
mediated inhibition of the MAPK pathway (U937 and ML-1) were not positive for the 
presence of phospho-ERK1/2, hence had an inactive MEK1/2-ERK1/2 pathway (RFI = 
1.41 and 1.51 for U937 and ML-1, respectively, compared to isotype control) (Fig. 6 C 
and D).  
Analysis of the ratio of phospho to total ERK1/2 in cell lysates of AML cell lines, an 
indicator of the activation level of the Ras-Raf-MEK1/2-ERK1/2 branch of the MAPK 
pathway, revealed the presence of a higher ratio of phospho to total ERK1/2 in AML cell 
lines sensitive to the LeTx-induced inhibition of the MAPK pathway (mean ratio 0.74) 
compared to cells resistant to the inhibition of this pathway (mean ratio 0.49) (Table 2).   
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Table 2. Sensitivity of human AML cell lines to LeTx (PrAg/LF) and activation level of 
the MAPK pathway illustrated by the ratio of phospho to total ERK1/2 levels. 
Cell line 
LeTx (PrAg/LF) 
(IC50;pmol/L) 
Ratio of Phospho to total 
Erk1/2 
HL60 13.0 1.00 
TF1-VSrc 15.0 0.74 
TF1-VRaf 16.0 0.73 
Mono-Mac-6 39.0 0.70 
SigM5 40.0 N/A 
ML-2 81.0 0.27 
TF1-HaRas 94.0 1.00 
ML-1 > 10000 0.31 
U937 > 10000 0.54 
KG-1 > 10000 N/A 
Mono-Mac-1 > 10000 0.62 
N/A: Not Available 
As illustrated in Table 2, all the LeTX-sensitive AML cell lines, except ML-2, had a ratio 
of phospho to total ERK1/2 higher than 0.7 indicating that more than 70% of total 
ERK1/2 in those cells is in the phosphorylated form, demonstrating a high level of 
activity of the MEK1/2-ERK1/2 branch of the MAPK pathway which correlates with the 
sensitivity of those cells to the inhibition of the MAPK pathway. On the other hand, 
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LeTx-resistant cell lines had a relatively lower activation level of the MEK1/2-ERK1/2 
branch of the MAPK pathway, as illustrated by lower ratios of phospho to total ERK1/2, 
which correlates with their resistance to the inhibition of that pathway. 
This indicates that phospho-ERK1/2 levels, which reflect the activation level of the 
MAPK pathway, may serve as a useful marker for predicting the sensitivity of AML cells 
to the inhibition of the MAPK pathway. However, as illustrated by the low ratio of 
phospho to total ERK1/2 in one of the LeTx-sensitive cell lines (ML2, 0.27) and the 
relatively high ratio in one of the LeTx-resistant cell lines (Mono-Mac-1, 0.6), the 
addiction of a tumor cell to a particular signaling pathway, i.e. its inability to survive its 
inhibition, is much more complex than its simple activation level in that cell.  
 
Analysis of Cell Death: 
To determine the mechanism of the cell death observed following the LF-mediated 
inhibition of the MAPK pathway in AML cells, we tested for caspase activation and 
annexin V/PI staining in our panel of AML cell lines following treatment with three 
different concentrations of LeTx (10,000, 300 and 4.5 pM) for 24 and 48 h. The four cell 
lines that did not show a cytotoxic response following treatment with LeTx in the 
proliferation inhibition assay, stained negatively with both PI and Annexin V, confirming 
the absence of cell death following LF-mediated inhibition of the MAPK pathway in 
these cell lines. On the other hand, in all seven LeTx-sensitive cell lines (TF1-vRaf, TF1-
vSrc, TF1-HaRas, HL60, SigM5, Mono-Mac-6 and ML-2), an increase in the percentage 
of cells stained with both annexin V and PI was observed, at both 24 and 48 h, in cells 
treated at the highest concentration of LeTx (10 nM) compared to controls, indicating 
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either necrotic or late-stage apoptotic cell death (Fig,7). However, staining for active 
caspases revealed a total absence of caspase activation in all AML cell lines tested, 
following treatment with LeTx for 24 and 48 h (Fig. 7). The absence of caspase 
activation, in addition to the loss of membrane integrity as evidenced by positive PI 
staining, indicate that LeTx-induced cytotoxicity in AML cells is mediated through 
caspase-independent, non-apoptotic mechanisms. 
 
A) 
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B) 
 
C) 
  
Figure 7. Analysis of the mechanism of LeTx-mediated cytotoxicity in TF1-vRaf cells 
using annexin V/PI (A) and active caspase staining (B) and in HL60 cells using annexin 
V/PI (C). TF1-vRaf and HL60 cells incubated with 10 nM LeTx for 24 or 48 h (right 
panel) stained positively with both annexin V (FL1-H) and PI (FL2-H). Incubation of 
LeTx-treated TF1-vRaf cells with a cell permeable, FITC-conjugated active caspase 
inhibitor revealed the absence of active caspases following incubation with LeTx (grey). 
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CHAPTER FOUR 
DISCUSSION 
In this study, we have shown that anthrax lethal toxin (LeTx) is highly cytotoxic to a 
majority of human AML cell lines through the LF-mediated inhibition of the MAP kinase 
pathway. Limited information exists regarding the importance of the MAPK pathway in 
AML cells and the potential targeting of AML through the inhibition of the MAPK 
pathway has not been sufficiently investigated so far (Zaidi SK, 2009) (Ricciardi M, 
2012) (Konopleva M, 2005). We have demonstrated that differential sensitivity of AML 
cell lines to anthrax lethal toxin was not due to the inability of the LF moiety to 
translocate into the cytosol, but rather to the differential sensitivity of AML cell lines to 
the LF-mediated inhibition of the MAP kinase pathway. When we replaced the catalytic 
domain of LF with the catalytic domain of Pseudomonas aeruginosa exotoxin A, which 
inhibits protein synthesis rather than the MAPK pathway, differential sensitivity was lost 
and all AML cell lines tested were sensitive to the combination of PrAg and FP59, 
demonstrating that differential sensitivity of AML cells to LeTx was due to the 
differential response of AML cell lines to the LF-mediated inhibition of the MAPK 
pathway. In addition, we have shown that the pattern of cytotoxicity of LeTx on our 
panel of AML cell lines was mimicked by the specific, small molecular weight MEK1/2 
inhibitor U0126, indicating that cytotoxicity of LeTx is mainly mediated through the 
inhibition of the MEK1/2-ERK1/2 branch of the MAPK pathway. Moreover, we have 
shown that incubation of AML cells with LeTx leads to a marked inhibition of the 
MEK1/2-ERK/12 branch of the MAPK pathway as evidenced by the absence of 
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phosphorylated ERK1/2 in cells incubated with LeTx for 10h as compared to non-treated 
cells.  
The four AML cell lines that proved to be resistant to the inhibition of the MAPK 
pathway by LeTx were sensitive to the inhibition of the PI3K/AKT pathway by 
LY294002, a small molecular weight PI3 kinase inhibitor. Interestingly, co-incubating 
AML cell lines with both LeTx and LY294002 did not show any significant increase in 
cytotoxicity compared to LY294002 alone. Therefore, the panel of AML cell lines tested 
consisted of two distinct populations, one sensitive to the inhibition of the MAPK 
pathway, the other sensitive to the inhibition of the PI3/AKT pathway with the 
simultaneous inhibition of both pathways not leading to any additive or synergistic 
effects. These findings are surprising since the inhibition of both the MEK1/2-ERK1/2 
pathway and the PI3K/Akt pathway has been shown to have additive or synergistic 
effects in a number of tumor types, including hepatocellular carcinoma, colorectal cancer, 
pancreatic adenocarcinoma and melanoma (Shimizu T, 2012) (Gedaly R, 2012) 
(Haagensen EJ, 2012) (Williams TM, 2012) Moreover, it has been shown that resistance 
to MEK inhibitors is mediated through the activation of the PI3k/Akt pathway in a 
number of tumors (Wee S, 2009).
30
 Inhibition of both the MEK1/2-ERK1/2 pathway and 
the PI3K/Akt pathway in AML cells has not been investigated to date. Our results 
demonstrate that AML cells are sensitive to the inhibition of either the MEK1/2-ERK1/2 
pathway or the PI3K/Akt pathway with no additive or synergistic effect for the 
simultaneous inhibition of both pathways. 
In addition to its cytotoxic effect on a majority of AML cell lines, we have shown that 
LeTx also induces cell cycle arrest in a large subset of cell lines, independently of their 
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sensitivity to the cytotoxic effects of the LF-mediated inhibition of the MAPK pathway. 
One of the four cell lines that did not show a cytotoxic response to LeTx, in addition to 
four of the seven cell lines that did show a cytotoxic response had an increase in the 
fraction of cells in the G0/G1 phase along with a decrease in the fraction of cells in the 
G2/M and S phases in surviving cells at the highest concentration compared to controls. 
We then determined the activity of the Ras-Raf-MEK1/2-ERK1/2 pathway in AML cell 
lines by assessing phospho-ERK1/2 levels using single cell intracellular staining and 
comparing it to the cytotoxic response of these cells to the LF-mediated inhibition of the 
MAPK pathway. Cell lines in which the LF-mediated inhibition of the MAPK pathway 
induced cytotoxicity were positive for phospho-ERK1/2 indicating an active Ras-Raf-
MEK1/2-ERK1/2 pathway while cell lines in which the inhibition of this pathway did not 
induce cytotoxicity were negative for phospho-ERK1/2. This indicates that sensitivity of 
AML cells to the LF-mediated inhibition of the MAPK pathway is determined by the 
activity of the MAPK pathway and that phospho-ERK1/2 levels may be used as a marker 
to predict sensitivity of AML cells to the inhibition of the MAPK pathway. Predicting a 
cells response to the inhibition of a signaling pathway, such as the MAPK pathway, may 
be more complicated than a simple determination of the activity of the pathway, however, 
in the absence of alternatives, this remains the only available means of assessing the 
importance of a particular pathway to the survival of cells. 
Analysis of the mechanism of cell death in AML cell lines following LF-mediated 
inhibition of the MAPK pathway revealed that LeTx induces caspase-independent, non-
apoptotic cell death in AML cells. Cells treated with LeTx for 24 h were positive for both 
Annexin V and PI while being negative for the presence of active caspases. Anthrax 
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lethal toxin has been shown to induce caspase-dependent, apoptotic cell death in a 
number of tumor types, including melanoma (Koo HM, 2002)
 
However, LeTx-mediated 
inhibition of the MAPK pathway has not been investigated in AML cells and the type of 
cell death induced by the LF-mediated inhibition of this pathway may be dependent on 
the tumor type. Furthermore, though some studies have shown that Ras inhibitors and 
MEK inhibitors do induce apoptosis in AML cell lines, the non-apoptotic cell death 
induced by LeTx in AML cells is not surprising knowing the different mechanism of 
action of LeTx which catalytically cleaves all MEKs leading to the complete inhibition of 
all branches of the MAPK pathway (James JA, 2003) (Milella M E. Z., 2002) (Morgan 
MA, 2001).
 
In this study we have shown that a majority of AML cell lines are sensitive to the LF-
mediated inhibition of the MAPK pathway, hence confirming the potential for selectively 
targeting this pathway in AML. Furthermore, we have demonstrated that LeTx-induced 
cytotoxicity in AML cells, following inhibition of the MAPK pathway, is non-apoptotic 
and is dependent on phospho-ERK1/2 levels in targeted cells. 
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